

Stm 天主教聖馬爾定醫院

化療處方集

最初出版日期:95.03

最後更新日期:108.03

癌別：口腔癌、口咽癌、下咽癌、鼻咽癌		
	最近改版日期	108.03
Induction	處方內容	<p>1. Cisplatin 60 mg/m² (N/S 500 c.c.; ≥ 4hrs) + [5-FU 1000 mg/m² (N/S 500 c.c.; ≥ 3hrs) + Leucovorin (LV) 100 mg (N/S 500 c.c.; ≥ 3hrs) * 4 doses q4wks (Cancer 1984;53:1819-24)</p> <p>2. 交通不便+不住院+poor compliance to oral UFUR: Cisplatin 60 mg/m² (N/S 500 c.c.; ≥ 4hrs) q4wks +[5-FU 1500 mg/m² (N/S 500 c.c.; ≥ 4hrs) + Leucovorin (LV) 200 mg(N/S 500 c.c.; ≥ 4hrs)] q2wks * II</p> <p>3. Cisplatin 60 mg/m² q4wks + UFUR 900-1100 mg/m²/d + LV (P.O.) 30 mg/d (健保條例)</p> <p>4. (A) ↔ (B) q2wks (A) Cisplatin 60 mg/ m² + Bleomycin 8 mg/m² (N/S 100 c.c.; 30 mins) + 5-FU 1500 mg/ m² (N/S 500 c.c.; ≥ 4hrs) + LV 200 mg (N/S 500 c.c.; ≥ 4hrs) (同上 3., v. 5-FU/LV 亦可以 oral UFUR” 與 “oral LV 取代)</p> <p>(B) Epirubicin 50 mg/m² (N/S 100 c.c.; 30 mins) + MTX 100 mg/m² (N/S 100 c.c.; 1 hr) (MTX 200 mg/ m², N/S 500 c.c.; ≥ 3 hrs; for high grade, extensive, multiple foci, R1 resection) + 5-FU 1500 mg/ m² + LV 200 mg (同上 3., v. 5-FU/LV 亦可以 “oral UFUR” 與 “oral LV” 取代) (European Journal of Cancer 1993 Vol.29 pp 704-708)</p> <p>5. Cisplatin 60 mg/m² /4 wks+ Docetaxel 35,40 mg/m² (N/S 100 c.c.; 1 hr)* II /4 wks + 5-FU/LV(dose as above) (JCO Nov.1999; 3503-3511) ;(健保條例)</p> <p>6. Cisplatin 60 mg/m²/4 wks + Docetaxel 35,40 mg/m² (N/S 100 c.c.; 1 hr)* II /4 wks + UFUR 900-1100 mg/m²/d + LV (P.O.) 30mg/d (健保條例)</p>

7.C/T for CCRT (combined with R/T) :

(A) Cisplatin 30 mg/ m² (N/S 500 c.c.; ≥ 3hrs) q wk * 4-6 doses (with R/T) (Cancer Nov.1 1990)

(B)Cisplatin 60 mg/m² (N/S 500 c.c.; ≥ 4hrs) + [5-FU 1000 mg/m² (N/S 500 c.c.; ≥ 3hrs) + Leucovorin (LV) 100 mg (N/S 500 c.c.; ≥ 3hrs) * 4 doses q4wks (Cancer 1984;53:1819-24)

(C)交通不便+不住院+poor compliance to oral UFUR:

Cisplatin 60 mg/m² (N/S 500 c.c.; ≥ 4hrs) q4wks +[5-FU 1500 mg/m² (N/S 500 c.c.; ≥ 4hrs) + Leucovorin (LV) 200 mg(N/S 500 c.c.; ≥ 4hrs)] q2wks * II

(D)Cisplatin 60 mg/m² q4wks + UFUR 900-1100 mg/m²/d + LV (P.O.) 30 mg/d (健保條例)

(E) (A)↔ (B) q2wks

(A) Cisplatin 60 mg/m² + Bleomycin 8 mg/m² (N/S 100 c.c.; 30 mins) + 5-FU 1500 mg/ m² (N/S 500 c.c.; ≥ 4hrs)+ LV 200 mg (N/S 500 c.c.; ≥ 4hrs) (同上 3., v. 5-FU/LV 亦可以 oral UFUR” 與 “oral LV 取代)

(B) Epirubicin 50 mg/m² (N/S 100 c.c.; 30 mins) + MTX 100 mg/m² (N/S 100 c.c.;1 hr) (MTX 200 mg/ m², N/S 500 c.c.; ≥ 3 hrs; for high grade, extensive, multiple foci, R1 resection) + 5-FU 1500 mg/ m² + LV 200 mg (同上 3., v. 5-FU/LV 亦可以“oral UFUR” 與 “oral LV” 取代) (European Journal of Cancer 1993 Vol.29 pp 704-708)

8.Consider Cetuximab 250 mg/m² run 2 hrs

癌別：口腔癌、口咽癌、下咽癌、鼻咽癌		
	最近改版日期	108.03
CCRT	處方內容	<p>C/T for CCRT (combined with R/T) :</p> <ol style="list-style-type: none"> 1. Cisplatin 30 mg/ m² (N/S 500 c.c.; ≥ 3hrs) q wk * 4-6 doses (with R/T) (Cancer Nov.1 1990) 2. Cisplatin 60 mg/m² (N/S 500 c.c.; ≥ 4hrs) + [5-FU 1000 mg/m² (N/S 500 c.c.; ≥ 3hrs) + Leucovorin (LV) 100 mg (N/S 500 c.c.; ≥ 3hrs) * 4 doses q4wks (Cancer 1984;53:1819-24) 3.交通不便+不住院+poor compliance to oral UFUR: Cisplatin 60 mg/m² (N/S 500 c.c.; ≥ 4hrs) q4wks +[5-FU 1500 mg/m² (N/S 500 c.c.; ≥ 4hrs) + Leucovorin (LV) 200 mg(N/S 500 c.c.; ≥ 4hrs)] q2wks * II 4.Cisplatin 60 mg/m² q4wks + UFUR 900-1100 mg/m²/d + LV (P.O.) 30 mg/d (健保條例) 5. (A)↔(B) q2wks (A) Cisplatin 60 mg/m² + Bleomycin 8 mg/m² (N/S 100 c.c.; 30 mins) + 5-FU 1500 mg/m² (N/S 500 c.c.; ≥ 4hrs)+ LV 200 mg (N/S 500 c.c.; ≥ 4hrs) (同上 3., v. 5-FU/LV 亦可以 oral UFUR” 與 “oral LV 取代) (B) Epirubicin 50 mg/m² (N/S 100 c.c.; 30 mins) + MTX 100 mg/m² (N/S 100 c.c.;1 hr) (MTX 200 mg/ m², N/S 500 c.c.; ≥ 3 hrs; for high grade, extensive, multiple foci, R1 resection) + 5-FU 1500 mg/ m² + LV 200 mg (同上 3., v. 5-FU/LV 亦可以“oral UFUR” 與 “oral LV” 取代) (European Journal of Cancer 1993 Vol.29 pp 704-708) 6.Consider Cetuximab 250 mg/m² run 2 hrs

癌別：口腔癌、口咽癌、下咽癌、鼻咽癌		
	最近改版日期	108.03
Adjuvant	處方內容	<p>1. Cisplatin 60 mg/m² (N/S 500 c.c.; ≥ 4hrs) + [5-FU 1000 mg/m² (N/S 500 c.c.; ≥ 3hrs) + Leucovorin (LV) 100 mg (N/S 500 c.c.; ≥ 3hrs) * 4 doses q4wks VI (Cancer 1984;53:1819-24)</p> <p>2. 交通不便+不住院+poor compliance to oral UFUR : Cisplatin 60 mg/m² (N/S 500 c.c.; ≥ 4hrs) q4wks +[5-FU 1500 mg/m² (N/S 500 c.c.; ≥ 4hrs) + Leucovorin (LV) 200 mg (N/S 500 c.c.; ≥ 4hrs)] q2wks * II VI</p> <p>3. Cisplatin 60 mg/m² q4wks + UFUR 900-1100 mg/m²/d + LV (P.O.) 30 mg/d VI (健保條例)</p> <p>4. (A) ↔ (B) q2wks VI (A) Cisplatin 60 mg/ m² + Bleomycin 8 mg/m² (N/S 100 c.c.; 30 mins) + 5-FU 1500 mg/ m² (N/S 500 c.c.; ≥ 4hrs) + LV 200 mg (N/S 500 c.c.; ≥ 4hrs) (同上 3., v. 5-FU/LV 亦可以 oral UFUR” 與 “oral LV 取代) (B) Epirubicin 50 mg/m² (N/S 100 c.c.; 30 mins) + MTX 100 mg/m² (N/S 100 c.c.; 1 hr) (MTX 200 mg/ m², N/S 500 c.c.; ≥ 3 hrs; for high grade, extensive, multiple foci, R1 resection) + 5-FU 1500 mg/ m² + LV 200 mg (同上 3., v. 5-FU/LV 亦可以 “oral UFUR” 與 “oral LV” 取代) (European Journal of Cancer 1993 Vol.29 pp 704-708)</p> <p>5. Cisplatin 60 mg/m² /4 wks+(自費)Docetaxel 35,40 mg/m² (N/S 100 c.c.; 1 hr)* II /4 wks + 5-FU/LV (dose as above) VI (JCO Nov.1999; 3503-3511)</p> <p>6. Cisplatin 60 mg/m²/4 wks +(自費)Docetaxel 35,40 mg/m² (N/S 100 c.c.; 1 hr)* II /4 wks + UFUR 900-1100 mg/m²/d + LV (P.O.) 30mg/d VI</p> <p>7. C/T for CCRT (combined with R/T) : (A) Cisplatin 30 mg/ m² (N/S 500 c.c.; ≥ 3hrs) q wk * 4-6 doses (with R/T) (Cancer Nov.1 1990) (B) Cisplatin 60 mg/m² (N/S 500 c.c.; ≥ 4hrs) + [5-FU 1000 mg/m² (N/S 500 c.c.; ≥ 3hrs) + Leucovorin (LV) 100 mg (N/S 500 c.c.; ≥ 3hrs) * 4 doses q4wks VI (Cancer 1984;53:1819-24)</p>

(C)交通不便+不住院+poor compliance to oral UFUR:

Cisplatin 60 mg/m² (N/S 500 c.c.; ≥ 4hrs) q4wks +[5-FU 1500 mg/m² (N/S 500 c.c.; ≥ 4hrs) + Leucovorin (LV) 200 mg(N/S 500 c.c.; ≥ 4hrs)] q2wks * II VI

(D)Cisplatin 60 mg/m² q4wks + UFUR 900-1100 mg/m²/d + LV (P.O.) 30 mg/d VI (健保條例)

(E) (A)↔ (B) q2wks VI

(A) Cisplatin 60 mg/ m² + Bleomycin 8 mg/m² (N/S 100 c.c.; 30 mins) + 5-FU 1500 mg/m² (N/S 500 c.c.; ≥ 4hrs) + LV 200 mg (N/S 500 c.c.; ≥ 4hrs) (同上 3., v. 5-FU/LV 亦可以 oral UFUR” 與 “oral LV 取代)

(B) Epirubicin 50 mg/m² (N/S 100 c.c.; 30 mins) + MTX 100 mg/m² (N/S 100 c.c.;1 hr) (MTX 200 mg/m², N/S 500 c.c.; ≥ 3 hrs; for high grade, extensive, multiple foci, R1 resection) + 5-FU 1500 mg/ m² + LV 200 mg (同上 3., v. 5-FU/LV 亦可以 “oral UFUR” 與 “oral LV” 取代) (European Journal of Cancer 1993 Vol.29 pp 704-708)

8.Consider Cetuximab 250 mg/m² run 2 hrs

癌別：口腔癌、口咽癌、下咽癌、鼻咽癌		
	最近改版日期	108.03
Palliative	處方內容	<p>1. Cisplatin 60 mg/m² (N/S 500 c.c.; ≥ 4hrs) + [5-FU 1000 mg/m² (N/S 500 c.c.; ≥ 3hrs) + Leucovorin (LV) 100 mg (N/S 500 c.c.; ≥ 3hrs) * 4 doses q4wks (Cancer 1984;53:1819-24)</p> <p>2. 交通不便+不住院+poor compliance to oral UFUR: Cisplatin 60 mg/m² (N/S 500 c.c.; ≥ 4hrs) q4wks +[5-FU 1500 mg/m² (N/S 500 c.c.; ≥ 4hrs) + Leucovorin (LV) 200 mg(N/S 500 c.c.; ≥ 4hrs)] q2wks * II</p> <p>3. Cisplatin 60 mg/m² q4wks + UFUR 900-1100 mg/m²/d + LV (P.O.) 30 mg/d (健保條例)</p> <p>4. (A) ↔ (B) q2wks (A) Cisplatin 60 mg/ m² + Bleomycin 8 mg/m² (N/S 100 c.c.; 30 mins) + 5-FU 1500 mg/ m² (N/S 500 c.c.; ≥ 4hrs) + LV 200 mg (N/S 500 c.c.; ≥ 4hrs) (同上 3., v. 5-FU/LV 亦可以 oral UFUR” 與 “oral LV 取代) (B) Epirubicin 50 mg/m² (N/S 100 c.c.; 30 mins) + MTX 100 mg/m² (N/S 100 c.c.; 1 hr) (MTX 200 mg/ m², N/S 500 c.c.; ≥ 3 hrs; for high grade, extensive, multiple foci, R1 resection) + 5-FU 1500 mg/ m² + LV 200 mg (同上 3., v. 5-FU/LV 亦可以 “oral UFUR” 與 “oral LV” 取代) (European Journal of Cancer 1993 Vol.29 pp 704-708)</p> <p>5. Cisplatin 60 mg/m² /4 wks+(自費) Docetaxel 35,40 mg/m² (N/S 100 c.c.; 1 hr)* II /4 wks + 5-FU/LV(dose as above) (JCO Nov.1999; 3503-3511)</p> <p>6. Cisplatin 60 mg/m²/4 wks + (自費) Docetaxel 35,40 mg/m² (N/S 100 c.c.; 1 hr)* II /4 wks + UFUR 900-1100 mg/m²/d + LV (P.O.) 30mg/d</p> <p>7. C/T for CCRT (combined with R/T) : (A) Cisplatin 30 mg/ m² (N/S 500 c.c.; ≥ 3hrs) q wk * 4-6 doses (with R/T) (Cancer Nov.1 1990) (B) Cisplatin 60 mg/m² (N/S 500 c.c.; ≥ 4hrs) + [5-FU 1000 mg/m² (N/S 500 c.c.; ≥ 3hrs) + Leucovorin (LV) 100 mg (N/S 500 c.c.; ≥ 3hrs) * 4 doses q4wks (Cancer 1984;53:1819-24)</p>

(C)交通不便+不住院+poor compliance to oral UFUR:

Cisplatin 60 mg/m² (N/S 500 c.c.; ≥ 4hrs) q4wks +[5-FU 1500 mg/m² (N/S 500 c.c.; ≥ 4hrs) + Leucovorin (LV) 200 mg(N/S 500 c.c.; ≥ 4hrs)] q2wks * II

(D)Cisplatin 60 mg/m² q4wks + UFUR 900-1100 mg/m²/d + LV (P.O.) 30 mg/d (健保條例)

(E) (A)↔ (B) q2wks

(A) Cisplatin 60 mg/ m² + Bleomycin 8 mg/m² (N/S 100 c.c.; 30 mins) + 5-FU 1500 mg/ m² (N/S 500 c.c.; ≥ 4hrs)+ LV 200 mg (N/S 500 c.c.; ≥ 4hrs) (同上 3., v. 5-FU/LV 亦可以 oral UFUR” 與 “oral LV 取代)

(B) Epirubicin 50 mg/m² (N/S 100 c.c.; 30 mins) + MTX 100 mg/m² (N/S 100 c.c.; 1 hr) (MTX 200 mg/m², N/S 500 c.c.; ≥ 3 hrs; for high grade, extensive, multiple foci, R1 resection) + 5-FU 1500 mg/ m² + LV 200 mg (同上 3., v. 5-FU/LV 亦可以 “oral UFUR” 與 “oral LV” 取代) (European Journal of Cancer 1993 Vol.29 pp 704-708)

8.Consider Cetuximab 250 mg/m² run 2 hrs